Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

rFVIIa

ApprovedSmall molecule

rFVIIa is one of 104 small molecule programs targeting Hemorrhage. It is currently in Approved.

3

Indications

6

Total Trials

1

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemorrhageActive, not recruiting

Intracerebral HemorrhageActive, not recruiting

Hemophilia aActive, not recruiting

HemorrhageApproved

Active, not recruiting

Intracerebral HemorrhagePhase 2

Active, not recruiting

Hemophilia aPhase 3

Active, not recruiting

Competition

Competitive Landscape

137 competitors in Hemorrhage

#DrugCompanyPhaseTrials

Cytotec

Cyklokapron

Activase

Betadine

BBecton, Dickinson and Company

Glypressin

Epoetin Beta

Ulipristal Acetate

rFVIIa

Platelets

LLeiden University Medical Center

Thyroxine

WWashington University School of Medicine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Prophylaxis

NCT04563520

Clinical

Trials by Indication[1]

Intracerebral Hemorrhage2 trials

Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT00128050·30 enrolled

"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy

Completed·—·Phase 2·NCT01359202·50 enrolled

Hemophilia A1 trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

Completed· Roche logo

Roche·Phase 3·NCT02622321·113 enrolled

Hemorrhage1 trial

rhuFVIIa in Post-partum Hemorrhage

Completed·—·Phase 4·NCT00370877·84 enrolled

Prophylaxis1 trial

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Recruiting·EEmory University·Phase 3·NCT04563520·5 enrolled

Anticoagulant1 trial

rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets

Unknown status·UUniversity Of Perugia·Phase 2·NCT00222625·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for rFVIIa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rFVIIa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rFVIIa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Roche

Related News